#ESMO22: Here are the disastrous data that crushed hopes for a $3.6B Bristol Myers combo deal
PARIS — A little more than four years after Bristol Myers Squibb proudly unveiled a $3.6 billion, next-gen I/O alliance with Nektar, including about half of that in cold, hard cash, investigators have turned up at ESMO with the full set of disastrous Phase III data that helped ice the whole deal.
We learned back in March that Opdivo plus Nektar’s IL-2 therapy bempeg flunked a Phase III melanoma study. Now we’re learning that the combo actually performed significantly worse than Opdivo alone, while raising added safety threats for the patients in the combo arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
